<International Circulation>: The COMPARE trial was recently published and we would like to know what you think that we have learned from this all-comers trial?
Prof. Smits: As you mentioned， it is an all-comers trial and it reflects real world conditions， which is important for clinicians， and it showed that we now have a drug-eluting stent available that has not improved safety but also efficacy. This is the first time in a drug-eluting stent trial where it was shown that we can improve both safety and efficacy.
上一页 [1] [2] [3] [4] [5] [6] 下一页
网友评论仅供其表达个人看法，并不表明国际循环同意其观点或证实其描述。 发表评论需登陆